Atopic Dermatitis

>

Latest News

Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update / image credit ©Arcutis Biotherapeutics
Roflumilast Cream 0.15% Receives Strong Recommendation for Atopic Dermatitis in AAD Guideline Update

June 26th 2025

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.

Investigational Respegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis
Investigational Rezpegaldesleukin Drives Early EASI Improvement and Symptom Relief in Adults with Moderate-to-Severe Atopic Dermatitis

June 25th 2025

Key Updates in Atopic Dermatitis for Primary Care
Key Updates in Atopic Dermatitis for Primary Care

June 13th 2025

Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD
Why the OX-40/OX-40L Pathway Matters in Atopic Dermatitis—and What’s Next: A Q&A with Johann Gudjonsson, MD, PhD

June 12th 2025

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

June 11th 2025

Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.